Library
Need for a proactive and structured approach to risk analysis when designing phase I trials.
22 July 2015. doid: 10.1136/bmj.h3899
Van den Bogert CA, Cohen AF
View publicationAdvancing the boundaries of clinical drug development
Wondering how we can help you? Reach out to us.
